IKNA
Closed
Ikena Oncology Inc
1.32
-0.02 (-1.49%)
Last Update: 01 Jul 2025 23:17:00
Yesterday: 1.34
Day's Range: 1.32 - 1.35
Send
sign up or login to leave a comment!
When Written:
3.61
Ikena Oncology Inc is a clinical-stage biopharmaceutical company that focuses on the discovery and development of cancer therapies. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology's pipeline includes several small molecule drug candidates that target key cancer pathways, including those involved in DNA damage repair, immune evasion, and tumor metabolism. The company's lead drug candidate, IK-930, is a potent and selective inhibitor of the ATR kinase, which is involved in DNA damage response and repair.
Ikena Oncology has partnerships with several academic institutions and biopharmaceutical companies to advance its drug discovery and development programs. The company has raised over $120 million in funding to date from investors such as Atlas Venture, OrbiMed Advisors, and New Enterprise Associates.
Ikena Oncology's mission is to develop innovative cancer therapies that can improve the lives of patients with cancer. The company is committed to advancing its pipeline of drug candidates through rigorous scientific research and clinical development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Ikena Oncology's pipeline includes several small molecule drug candidates that target key cancer pathways, including those involved in DNA damage repair, immune evasion, and tumor metabolism. The company's lead drug candidate, IK-930, is a potent and selective inhibitor of the ATR kinase, which is involved in DNA damage response and repair.
Ikena Oncology has partnerships with several academic institutions and biopharmaceutical companies to advance its drug discovery and development programs. The company has raised over $120 million in funding to date from investors such as Atlas Venture, OrbiMed Advisors, and New Enterprise Associates.
Ikena Oncology's mission is to develop innovative cancer therapies that can improve the lives of patients with cancer. The company is committed to advancing its pipeline of drug candidates through rigorous scientific research and clinical development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!